Gilead gets in on the mi­cro­bio­me game with a $38M pact, up to $1.5B in mile­stones

In what had been shap­ing up to be a ma­jor year for mi­cro­bio­me biotechs, Gilead is get­ting in on the ac­tion.

Amer­i­ca’s new­ly most watched big biotech an­nounced a four-year, $38 mil­lion up­front pact with Sec­ond Genome to iden­ti­fy bio­mark­ers that can mea­sure clin­i­cal re­sponse to Gilead’s in­flam­ma­tion and fi­bro­sis drugs, among oth­ers, and to find up to 5 new in­flam­ma­to­ry bow­el dis­ease tar­gets or drug can­di­dates. If all five of those can­di­dates reach mar­ket — a rather un­like­ly oc­cur­rence — the deal could be worth up to $1.5 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.